Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 8
HGH vs tesamorelin: what the research says
After six months of tesamorelin, is switching to rhGH the right call? The IVF literature on growth hormone adjuvant use is thinner than the community assumes.
Ipamorelin Q3 2026: what changed
Four peer-reviewed 2026 reviews name ipamorelin in clinical framing. Regulatory status is unchanged and the evidence gap remains open.
Lilly and Resilience: $750M GLP-1 capacity
Eli Lilly and contract manufacturer Resilience announced a $750M Cincinnati expansion adding 400 jobs to GLP-1 injectable production. What it means for supply.
PT-141 2026-Q3: what changed this quarter
A new meta-analysis, a commentary on male use, and Palatin obesity-combination data: three developments that moved the bremelanotide picture in Q3 2026.
Semaglutide cut heavy drinking in AUD trial
The SEMALCO trial found semaglutide reduced heavy drinking days by 41 percentage points versus 26 on placebo in adults with AUD and obesity.
Semaglutide in children: Iceland cohort
Iceland's 2026 nationwide cohort found subsidised semaglutide reversed BMI in children with grade 2 obesity; 63% hit clinically meaningful reductions.
How semaglutide is measured in plasma
A 2026 HPLC-MS/MS assay measures semaglutide in plasma at 5-200 ng/mL. Why validated bioanalytical methods matter for pharmacokinetics and product quality.
Semax Q3 2026: what changed
Q3 2026 update on Semax: new preclinical papers on spinal cord injury and Alzheimer's, plus the FDA PCAC meeting that reviewed Semax for the 503A bulks list.
TB-500 Q3 2026: what changed
Q3 2026 update on TB-500: four new 2026 reviews, the Topol cancer-signal status, the FDA PCAC July meeting, and WADA prohibition unchanged.
Tesamorelin Q3 2026: what changed
Q3 2026 on tesamorelin: a meta-analysis of four HIV lipodystrophy trials, a brain-connectivity pilot, a frailty trial protocol, and unchanged regulatory status.
Tesamorelin and visceral fat: the evidence
FDA-approved for HIV lipodystrophy only. What the trial evidence covers, what it does not, and what to ask a clinician.
Tirzepatide Q3 2026: what changed
EMA cardiovascular assessment, paediatric label extension, SURMOUNT-5 quality-of-life data, and the GIP mechanism question: Q3 2026 catch-up.